Risk factors
OnKure Therapeutics (OKUR) risk factors
Item 1A of every OnKure Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors77 risks6 new8 dropped11 reworded
Capital runway extends only into the fourth quarter of 2026, creating going concern doubt. Reliance centers on advancing product candidate OKI-219 through Phase 1 trials.
Filed Mar 12, 2026 - FY2024 10-K risk factors79 risks
Clinical-stage biopharmaceutical company with no approved products, relying primarily on lead candidate OKI-219 in Phase 1 trials.
Filed Mar 10, 2025